| | May 8, 2014 — DEERFIELD, Ill., - The Board of Directors of Baxter International Inc. (NYSE:BAX) declared a quarterly dividend of $0.52 per Baxter common share, representing a six percent increase.
This increase results in an annual dividend rate of $2.08 per diluted share. Baxter has more than doubled the dividend since 2008, and the new rate maintains a dividend payout ratio of approximately 40 percent. The dividend is payable on July 1, 2014 to shareholders of record as of June 6, 2014.
Baxter continues to generate strong cash flow and has returned significant value to shareholders in the form of dividends and share repurchases over the last several years. Since 2008, the company has returned more than
$13 billion to shareholders through share repurchases of $8.6 billion (or approximately 152 million shares) and dividends totaling more than
$4.5 billion.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning Baxter's dividend. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continued strength in the company's financial position, including cash flows; future decisions of the board of directors of the company to continue payments to shareholders in the form of a dividend on a quarterly or other basis relative to alternative uses of funds; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. | |
